Login / Signup

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial.

Le XiaoXuequan ZhuAmy GillespieYuan FengJingjing ZhouXu ChenYuanyuan GaoXueyi WangXiancang MaChengge GaoYunshi XieXiaoping PanYan BaiXiufeng XuGang WangRunsen Chen
Published in: Psychological medicine (2020)
After 8 weeks follow-up, paroxetine monotherapy, mirtazapine monotherapy and paroxetine/mirtazapine combination therapy were equally effective in non-improvers at 2 weeks. The results of this trial do not support a recommendation to routinely offer additional treatment or a switch in treatment strategies for MDD patients who do not show early improvement after 2 weeks of antidepressant treatment.
Keyphrases
  • combination therapy
  • major depressive disorder
  • double blind
  • clinical trial
  • open label
  • phase iii
  • phase ii
  • placebo controlled
  • bipolar disorder
  • study protocol
  • randomized controlled trial
  • gestational age